Product image of Lenalidomid Glenmark (Lenalidomide) supplied by GNH India

Lenalidomid Glenmark

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomid Glenmark (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomid Glenmark, is an immunomodulatory drug presented as a tablet for oral use. It is used in the treatment of certain blood cancers, primarily multiple myeloma and myelodysplastic syndromes, in adult patients.
GNH India supplies Lenalidomid Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Glenmark Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomid Glenmark is an immunomodulatory agent indicated for specific hematologic malignancies.

  • Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease.
  • Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and corrects cytopenias.
  • Maintenance Therapy after Autologous Stem Cell Transplant in Multiple Myeloma: prolongs remission duration.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, prompting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to altered cytokine production, enhanced natural killer and T‑cell activity, inhibition of angiogenesis, and direct anti‑tumor effects in malignant plasma cells and myelodysplastic clones.

Side Effects

Lenalidomid Glenmark may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels leading to easy bruising.
  • Anemia: decreased red blood cells causing weakness.
  • Diarrhea: loose stools that may affect hydration.
  • Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: profound immune suppression requiring medical intervention.
  • Severe thrombocytopenia: significant bleeding risk.
  • Secondary primary malignancies: emergence of new cancers.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatotoxicity: elevated liver enzymes or liver injury.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters regularly.

  • Pregnancy contraindication: teratogenic; ensure effective contraception for women of childbearing potential.
  • Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients.
  • Hematologic monitoring: perform complete blood counts weekly during the first two cycles.
  • Renal impairment: adjust dose or avoid use in severe renal dysfunction.
  • Drug interactions: review concomitant medications for CYP3A4 modulators.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenalidomid Glenmark can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Thalidomide: additive teratogenic and neurotoxic effects.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lenalidomide exposure.
  • Anticoagulants (e.g., warfarin, DOACs): heightened risk of thromboembolic events.
  • Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels.
  • NSAIDs: increased bleeding tendency when thrombocytopenia is present.
  • Antihypertensives: possible additive hypotensive effect.
  • Digoxin: monitor serum levels due to potential pharmacodynamic changes.

Frequently Asked Questions

Lenalidomid Glenmark is prescribed for adult patients with multiple myeloma, including relapsed or refractory disease, and for myelodysplastic syndromes that have a deletion of chromosome 5q. It may also be used as maintenance therapy after autologous stem cell transplantation in multiple myeloma.

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, enhances immune cell activity, inhibits new blood‑vessel formation, and ultimately exerts anti‑tumor effects against malignant plasma cells and dysplastic marrow clones.

The specific dose and schedule of Lenalidomid Glenmark are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions precisely.

Lenalidomid Glenmark is classified as pregnancy category X because it is known to cause birth defects and fetal harm. It should not be used by pregnant women, and effective contraception is required for women of childbearing potential. The drug is also not recommended while breastfeeding, as it may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomid Glenmark belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or used after other regimens. Compared with thalidomide, lenalidomide has a more favorable side‑effect profile, especially regarding peripheral neuropathy, while maintaining strong anti‑myeloma activity.

Lenalidomid Glenmark tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia leading to infection or bleeding, secondary primary malignancies, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events.

Lenalidomid Glenmark should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with severe renal impairment without dose adjustment, and those with uncontrolled active infections. It is also contraindicated in patients receiving thalidomide concurrently due to additive teratogenic risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT